These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26646072)

  • 21. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece.
    Lambadiari V; Ozdemir Saltik AZ; de Portu S; Buompensiere MI; Kountouri A; Korakas E; Sharland H; Cohen O
    Diabetes Technol Ther; 2022 May; 24(5):316-323. PubMed ID: 34962140
    [No Abstract]   [Full Text] [Related]  

  • 22. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):934-939. PubMed ID: 30064713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
    Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
    Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy.
    Danne T; Kordonouri O; Holder M; Haberland H; Golembowski S; Remus K; Bläsig S; Wadien T; Zierow S; Hartmann R; Thomas A
    Diabetes Technol Ther; 2011 Nov; 13(11):1129-34. PubMed ID: 21827318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcome and Cost-Effectiveness Analysis of CSII Versus MDI in Children and Adolescent With Type 1 Diabetes Mellitus in a Public Health Care System of China.
    Hu S; Yang H; Chen Z; Leng X; Li C; Qiao L; Lv W; Li T
    Front Endocrinol (Lausanne); 2021; 12():604028. PubMed ID: 33859614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
    Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
    Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
    Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
    Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting.
    Gardner D; Lakkad M; Qiu Z; Inoue Y; Rama Chandran S; Wherry K
    Diabetes Technol Ther; 2024 May; 26(5):324-334. PubMed ID: 38215206
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
    Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
    Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Winn A; Zarei P; O'Grady M; Huang ES
    Diabetes Care; 2018 Jun; 41(6):1227-1234. PubMed ID: 29650803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study.
    Picard S; Hanaire H; Baillot-Rudoni S; Gilbert-Bonnemaison E; Not D; Reznik Y; Guerci B
    Diabetes Technol Ther; 2016 Mar; 18(3):127-35. PubMed ID: 26950530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with type 1 diabetes.
    Zhang L; Leng X; Tian F; Xiao D; Xuan J; Yang H; Liu J; Chen Z
    Postgrad Med; 2022 Aug; 134(6):627-634. PubMed ID: 35695267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2018; 18(2):1-160. PubMed ID: 29541282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
    St Charles M; Lynch P; Graham C; Minshall ME
    Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
    Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
    N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
    Del Prato S; Giorgino F; Szafranski K; Poon Y
    Diabetes Obes Metab; 2024 Sep; 26(9):3633-3641. PubMed ID: 38853717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.
    Giménez M; Elías I; Álvarez M; Quirós C; Conget I
    Endocrinol Diabetes Nutr; 2017; 64(7):377-383. PubMed ID: 28745609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.